



Guidance for management of bleeding and emergency surgery in patients taking direct oral anticoagulants (DOACs).

Document Author: T+A committee

Approved by: Medicines Management Board

Approval Date: 22nd March 2016

Review Date: 22nd March 2018

Document No: 1854

1 Introduction

The direct oral anticoagulants currently available inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban and edoxaban). They are licensed for the treatment and prevention of venous thrombo-embolism and prevention of stroke in patients who have non-valvular atrial fibrillation. With the exception of dabigatran, at present there are no direct means of reversing their anti-coagulant effect.

Dabigatran can be reversed by the administration of a monoclonal antibody idarucizumab (Praxbind®). For other direct oral anticoagulants, prothrombin complex concentrate has been shown to correct reduced thrombin generation in healthy volunteers and *in vitro* studies, but studies demonstrating a reduction in bleeding are lacking. The fXa specific reversal agent, andexanet alfa (Ondexxya®) has recently been approved for the reversal of apixaban and rivaroxaban (not edoxaban) within the EU. Although there are no direct comparisons with PCC, indirect comparison has shown andexanet to reduce mortality in GI and cerebral haemorrhage, but has no impact on long term disability in cerebral haemorrhage. As a result, NICE have appraised the agent, and approved its use in the management of life threatening GI bleed, associated with apixaban and rivaroxaban use. However, given the absence of high quality comparative data, the measures outlined in this guideline cannot be guaranteed to completely reverse the anti-coagulant effect.

2 Guidance

Firstly it is important to establish when the patient last ingested any medication. In the setting of normal renal function, 24 hours is likely to be sufficient for clearance of the of apixaban, edoxaban and rivaroxaban and 24-48 hours for dabigatran. If surgery or other invasive procedure is required, if possible this should be delayed for at least 24 hours. If a delay is not possible, or there is bleeding which threatens serious harm, proceed as outlined in Figure 1 for dabigatran and Figure 2 for rivaroxaban, apixaban and edoxaban.

Figure 1

Emergency reversal of dabigatran

Take blood samples for FBC, Group and Screen, PT, APTT, Fibrinogen, TCT and dabigatran level, renal function and liver function. State clearly on request form "Bleeding on dabigatran."

NB: A normal TCT indicates negligible amounts of dabigatran are present and no further action is required to reverse the effect. Drug levels will be processed during normal working hours.

Ingestion within preceding 2 hours?

If "yes," consider administering oral activated charcoal

General measures:

Stop drug

Apply local pressure

Administer tranexamic acid 1g iv (NOT if bleeding from renal tract)

Consider involvement of interventional radiology to embolise bleeding point

Life threatening bleeding or emergency surgery which can not be delayed:

Administer 5 g of idarucizumab iv (see appendix 2 for dosing)*

Repeat APTT and TCT post administration; if these remain abnormal, consider a second 5 g dose if there is ongoing bleeding or the risk of bleeding remains high.

***Discuss with on-call Haematologist via consultant to consultant discussion**

Accessed via Morriston Out of Hours Omnicell

Accessed via emergency cupboard in Singleton/NPT

Figure 2

Emergency reversal of oral direct Xa inhibitors

Take blood samples for FBC, Group and Screen, PT, APTT, Fibrinogen, drug level, renal function and liver function. State clearly on request form "Bleeding on rivaroxaban," "Bleeding on apixaban," or "Bleeding in edoxaban" as appropriate.

NB An abnormal PT means there is likely to be a therapeutic amount of the drug present; a normal PT does not exclude it. Drug levels will be processed during normal working hours.

General measures:

Stop drug

Apply local pressure

Administer tranexamic acid 1g iv (NOT if bleeding from renal tract)

Consider involvement of interventional radiology to embolise bleeding point

Life threatening GI bleeding on apixaban or rivaroxaban:

Give andexanet alfa (see appendix 2 for dosing) *

***Discuss with on-call Haematologist via consultant to consultant discussion**

Accessed via Morriston Out of Hours Omnicell

Other life threatening bleeding or emergency surgery which can not be delayed:

Give 50 units/Kg prothrombin complex concentrate (max 3000 Units)*

****Discuss with on-call Haematologist via consultant to consultant discussion**

Appendix 1: Administration of Idarucizuma (Praxbind®):

Idarucizumab is available from the Morriston Out of Hours Omnicell, and can only be accessed following approval from the on-call hematology consultant

Praxbind is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required:

- For emergency surgery/urgent procedures;
- In life-threatening or uncontrolled bleeding

Step 1: Prescribe the required dose as per the below table

DOSE:

5g (i.e. two vials of 2.5g/50ml)

Step 2: Prepare the product and administer

Reconstitution of vial: The product is available as a ready to administer solution, and has an integrated hanger to facilitate administration

Administration:

- **IV injection:** Give the contents of two vials consecutively, each over a period of 3-5 minutes
- OR
- **IV infusion:** Give the contents of two vials consecutively, each over a period of 5-10 minutes

Step 3: Repeat if indicated

Administration of a second 5 g dose of idarucizumab may be considered in the following situations:

- recurrence of clinically relevant bleeding together with prolonged clotting times, or
- if potential re-bleeding would be life-threatening and prolonged clotting times are observed, or
- patients require a second emergency surgery/urgent procedure and have prolonged clotting times

Step 4: Consider when oral anticoagulation to re-start

Pradaxa (dabigatran etexilate) treatment can be re-initiated 24 hours after administration of idarucizumab, if the patient is clinically stable and adequate haemostasis has been achieved.

After administration of idarucizumab, other antithrombotic therapy (e.g. low-molecular weight heparin) can be started at any time, if the patient is clinically stable and adequate haemostasis has been achieved.

Appendix 2: Administration of andexanet alfa (Ondexxya):

Andexanet alfa is available from the Morriston Out of Hours Omnicell, and can only be accessed following approval from the on-call hematology consultant

Step 1: Calculate whether a HIGH or LOW dose regime is required

For apixaban:

FXa inhibitor	Last dose	Timing of last dose before Ondexxya initiation	
		< 8 hours or unknown	≥ 8 hours
Apixaban	≤ 5 mg	Low dose	Low dose
	> 5 mg/ Unknown	High dose	

For rivaroxaban:

FXa inhibitor	Last dose	Timing of last dose before Ondexxya initiation	
		< 8 hours or unknown	≥ 8 hours
Rivaroxaban	≤ 10 mg	Low dose	Low dose
	> 10 mg/ Unknown	High dose	

Step 2: Prescribe the required dose as per the below table

Table 1: Dosing regimens

	Initial intravenous bolus	Continuous intravenous infusion	Total number of 200 mg vials needed
Low dose	400 mg at a target rate of 30 mg/min	4 mg/min for 120 minutes (480 mg)	5
High dose	800 mg at a target rate of 30 mg/min	8 mg/min for 120 minutes (960 mg)	9

Step 3: Prepare the product

Reconstitution of vial: Reconstitute each vial using 20ml water for injections, using 20 gauge (or larger) needles, aiming the flow to the inside wall of the vial to minimise foam. Swirl for 3 to 5 minutes. **(DO NOT SHAKE)**

Administration: May be via a syringe pump or an IV bag with infusion pump using a 0.2 or 0.22 micron in-line polyethersulfone (PES) or equivalent low protein- binding filter


- **For administration using a syringe pump:** Withdraw the required volume of the reconstituted solution into a 50mL syringe. For high dose therapy, you may need two syringes for the loading dose and two for the maintenance dose.
- **For administration using an IV bag:** Use large volume syringes to transfer the reconstituted dose into an empty polyolefin (PO) or PVC infusion bag (150mL or larger). A separate bag is recommended for the loading and maintenance dose



Swansea Bay University Health Board

Authorisation Form for Publication onto COIN

PLEASE ENSURE THAT ALL QUESTIONS ARE ANSWERED – IF NOT APPLICABLE PLEASE PUT N/A

COIN ID.	1854
Title.	Guidance for the Management of Bleeding and Emergency Surgery in Patients taking Direct Oral Anticoagulants (DOACs).
Name and Signature of Author/Chair of Group or Committee.	Thrombosis and Anticoagulation Committee
Name and Signature of Lead Pharmacist.	Kieron Power 
Please specify whether the document is New, Revised or a Review of a previous version.	Revised
Please specify the section on COIN where you wish the document to be published.	Specialties/Haematology/Surgery/Medicine
Please sign to confirm that the document has been authorised by an approved governance process in a specialty or delivery unit.	Thrombosis and Anticoagulation Committee Medicines Management Board
Has NICE guidance been considered/referenced when producing this guidance? If yes, please state the title or reference number.	N/A
Is the document relevant to the GP Portal?	Yes
Equality Statement (Mandatory for Policies). ⁽¹⁾	N/A
Please specify keywords to assist with searching. ⁽²⁾	Anticoagulation, Reversal, DOAC, Idarucizumab, Andexanet Alfa, Bleeding.
Published.	September 2016
Last Review.	June 2021
Next Review/Expiry Date.	April 2023

(1) All policies need to comply with the Policy for the production, consultation, approval, publication and dissemination of strategies, policies, protocols, procedures and guidelines

(2) Relevant keywords will assist COIN users with searching for documents.